Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of oncology and immunology therapeutics, with a primary strategic emphasis on the China market. The company operates in the biotechnology and pharmaceutical industries, targeting cancers and immune-related diseases with high unmet medical need. CASI’s business model centers on in-licensing, developing, and commercializing late-stage drug candidates, particularly those that can leverage regulatory and market opportunities in Greater China.
The company’s primary revenue drivers are product sales and licensing-related income from approved or late-stage therapeutic assets, as well as milestone and collaboration payments where applicable. CASI positions itself as a bridge between Western-developed pharmaceutical assets and the Chinese healthcare market, aiming to accelerate time-to-market through localized clinical development and regulatory execution. Founded in 1991 (originally as EntreMed, Inc.), the company underwent a strategic transformation beginning in the mid-2010s, rebranding as CASI Pharmaceuticals and refocusing its operations on oncology and China-centric commercialization.
Business Operations
CASI conducts its operations through integrated research, development, regulatory, and commercial activities, with a particular emphasis on late-stage clinical development and commercialization. Its core business is organized around oncology product candidates and approved therapies, including internally developed and in-licensed assets. Key products have included Evomela® (melphalan for injection) and CNCT19 (a CAR-T therapy), though the commercial and development status of specific assets has evolved over time and, in some cases, remains subject to regulatory and market uncertainties.
The company operates both domestically in the United States and internationally, with its most significant operational and commercial focus in China. CASI controls clinical, regulatory, and commercial rights to certain products in defined territories, primarily Greater China. It has historically relied on partnerships with contract manufacturing organizations, clinical research organizations, and regional collaborators rather than owning large-scale manufacturing infrastructure. Data inconclusive based on available public sources regarding the current scale of active commercial partnerships following recent restructuring efforts.
Strategic Position & Investments
CASI’s strategic direction has emphasized capital efficiency, portfolio rationalization, and prioritization of assets with near- to mid-term commercial potential in oncology. Growth initiatives have included selective investment in late-stage clinical programs and regulatory approvals in China, as well as efforts to out-license or partner non-core assets. The company has also undertaken restructuring initiatives to reduce operating expenses and extend cash runway, reflecting broader challenges in the small-cap biotechnology sector.
Historically, CASI has made targeted investments and acquisitions to build its oncology pipeline, including rights to Evomela® and CAR-T-related programs through subsidiary structures. Emerging technologies of interest have included cell therapies and reformulated chemotherapeutics, though the extent of ongoing investment in these areas has varied over time. Data inconclusive based on available public sources regarding active acquisition activity or new platform investments in the most recent fiscal periods.
Geographic Footprint
CASI is headquartered in Rockville, Maryland, United States, and maintains a significant operational presence in China, which represents its most strategically important market. The company’s geographic footprint reflects its dual focus on Western drug development standards and Eastern commercialization opportunities. Clinical trials, regulatory filings, and commercial activities have been concentrated in mainland China, with supporting functions in the U.S.
Beyond the U.S. and China, CASI’s international footprint has been limited, with no material long-term commercial operations reported in Europe, Latin America, or Africa. Its global influence is primarily derived from cross-border licensing arrangements and regulatory interactions rather than broad multinational infrastructure.
Leadership & Governance
CASI is led by an executive team with experience in pharmaceutical development, regulatory affairs, and China-focused market strategy. Leadership has emphasized disciplined capital allocation, regulatory execution, and alignment with shareholder interests during periods of operational transition. The board of directors oversees corporate governance, strategic planning, and compliance with public company reporting requirements.
Key executives include:
- Wei-Wu He, Ph.D. – President and Chief Executive Officer
- Stanley Sun – Chief Financial Officer
- Rui Huang, Ph.D. – Senior Vice President, Clinical Development
- Bo Zhang – Vice President, Regulatory Affairs
Data inconclusive based on available public sources regarding recent changes to executive roles or board composition beyond publicly disclosed filings and company communications.